​

Orchestra BioMed (OBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

OBIO Stock Forecast

Orchestra BioMed (OBIO) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $12.00, with a high of $12.00 and a low of $12.00. This represents a 342.80% increase from the last price of $2.71.

$2 $4 $6 $8 $10 $12 High: $12 Avg: $12 Low: $12 Last Closed Price: $2.71

OBIO Stock Rating

Orchestra BioMed stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

OBIO Price Target Upside V Benchmarks

TypeNameUpside
StockOrchestra BioMed342.80%
SectorHealthcare Stocks 13.55%
IndustryBiotech Stocks 49.00%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$12.00
Last Closing Price$2.71$2.71$2.71
Upside/Downside--342.80%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 25331--7
Sep, 25331--7
Aug, 2534---7
Jul, 2534---7
Jun, 2534---7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 20, 2025Marie ThibaultBTIG$12.00$4.35175.86%342.80%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 04, 2025H.C. WainwrightBuyBuyhold
Apr 23, 2025H.C. WainwrightBuyBuyhold
Mar 20, 2025BTIGBuyinitialise
Jan 02, 2025BarclaysOverweightinitialise
Aug 22, 2024H.C. WainwrightBuyinitialise
Jul 24, 2024B. RileyBuyinitialise

Financial Forecast

EPS Forecast

$-20 $-16 $-12 $-8 $-4 $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.24$-1.48-----
Avg Forecast$-13.86$-1.48$-1.66$-1.92$-1.72$-1.66$-0.99
High Forecast$-9.43$-1.44$-1.65$-1.69$-1.06$-1.03$-0.61
Low Forecast$-18.00$-1.51$-1.67$-2.06$-2.39$-2.31$-1.38
Surprise %-83.84%------

Revenue Forecast

$0 $8M $16M $24M $32M $40M Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.53M$2.76M$2.64M----
Avg Forecast$4.30M$3.53M$3.19M$3.84M$3.89M$4.02M$27.27M
High Forecast$5.29M$4.33M$3.37M$5.01M$5.07M$5.24M$35.49M
Low Forecast$3.25M$2.72M$2.78M$2.71M$2.75M$2.84M$19.25M
Surprise %-17.93%-21.78%-17.24%----

Net Income Forecast

$-600M $-480M $-360M $-240M $-120M $0 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-33.61M$-49.12M$-61.02M----
Avg Forecast$-460.50M$-49.12M$-55.12M$-62.30M$-69.45M$-64.38M$-32.89M
High Forecast$-313.17M$-47.95M$-54.78M$-56.25M$-35.23M$-34.06M$-20.31M
Low Forecast$-598.07M$-50.25M$-55.45M$-68.35M$-79.40M$-76.78M$-45.79M
Surprise %-92.70%-10.72%----

OBIO Forecast FAQ

Is Orchestra BioMed stock a buy?

Orchestra BioMed stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Orchestra BioMed is a favorable investment for most analysts.

What is Orchestra BioMed's price target?

Orchestra BioMed's price target, set by 4 Wall Street analysts, averages $12 over the next 12 months. The price target range spans from $12 at the low end to $12 at the high end, suggesting a potential 342.80% change from the previous closing price of $2.71.

How does Orchestra BioMed stock forecast compare to its benchmarks?

Orchestra BioMed's stock forecast shows a 342.80% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the biotech stocks industry (49.00%).

What is the breakdown of analyst ratings for Orchestra BioMed over the past three months?

  • October 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 42.86% Strong Buy, 57.14% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Orchestra BioMed’s EPS forecast?

Orchestra BioMed's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.92, marking a 0% decrease from the reported $0 in 2024. Estimates for the following years are $-1.72 in 2026, $-1.66 in 2027, and $-0.99 in 2028.

What is Orchestra BioMed’s revenue forecast?

Orchestra BioMed's average annual revenue forecast for its fiscal year ending in December 2025 is $3.84M, reflecting a 45.73% increase from the reported $2.64M in 2024. The forecast for 2026 is $3.89M, followed by $4.02M for 2027, and $27.27M for 2028.

What is Orchestra BioMed’s net income forecast?

Orchestra BioMed's net income forecast for the fiscal year ending in December 2025 stands at $-62.3M, representing an 2.09% increase from the reported $-61.024M in 2024. Projections indicate $-69.451M in 2026, $-64.384M in 2027, and $-32.893M in 2028.